With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.142643-29-6,3-(Boc-aminomethyl)piperidine,as a common compound, the synthetic route is as follows.
Step 1. Preparation of tert-butvlin-(cvclopropvlmethvnpiperidin-3-vl1methyl)carbamate; ,NHNCH3O CH3[114] To a dry 10 mL round-bottom flask was added 3-/V-(tert-butoxycarbonylaminomethylpiperidine (500 mg, 2.33 mmol) followed by anhydrous dichloroethane (5.0 mL). The mixture wasstirred at rt under an atmosphere of N2 for 5 min, and then cyclopropanecarboxaldehyde (0.17 mL,2.33 mmol) and glacial acetic acid (0.80 mL, 14.0 mmol) were added. After stirring for 10 min,NaB(OAc)3H (1.98 g, 9.33 mmol) was added, and the milky white reaction mixture was stirred for15 h. The mixture was quenched with saturated aq Na2CO3 (10 mL) and was extracted withCH2CI2 (3 x 20 mL). The combined organic layers were washed with water (2 x 20 mL), dried overMgSO4> filtered, and concentrated under reduced pressure. Purification by flash silica gelchromatography (95% CH2CI2: 5% 2M NH3 in MeOH) gave the product as a yellow oil (388 mg,62%). R,= 0.23 (97% CH2CI2: 3% 2M NH3 in MeOH); 1H NMR (300 MHz, CDCI3) 6 4.60 (br s,351 H), 3.05-2.96 (m, 4H), 2.27 (d, 2H), 1 .96 (dd, 1 H), 1 .76-1 .61 (m, 5H), 1 .44 (s, 9H), 0.98-0.85 (m,2H), 0.55-0.49 (m, 2H), 0.13-0.09 (dd, 2H); ES-MS m/z269 (MH+).
As the paragraph descriping shows that 142643-29-6 is playing an increasingly important role.
Reference£º
Patent; BAYER PHARMACEUTICALS CORPORATION; WO2006/12577; (2006); A2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem